[1]
|
Satsangi, J., Silverberg, M.S., Vermeire, S. and Colombel, J.F. (2006) The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut, 55, 749-753. https://doi.org/10.1136/gut.2005.082909
|
[2]
|
Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association (2021) Chinese Consensus on Diagnosis and Treatment in Inflammatory Bowel Disease (2018, Beijing). Journal of Digestive Diseases, 22, 298-317. https://doi.org/10.1111/1751-2980.12994
|
[3]
|
Cosnes, J., Gower-Rousseau, C., Seksik, P. and Cortot, A. (2011) Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology, 140, 1785-1794. https://doi.org/10.1053/j.gastro.2011.01.055
|
[4]
|
Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. (2012) Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology, 142, 46-54.e42. https://doi.org/10.1053/j.gastro.2011.10.001
|
[5]
|
Zhang, Y.Z. and Li, Y.Y. (2014) Inflammatory Bowel Disease: Pathogenesis. World Journal of Gastroenterology, 20, 91-99. https://doi.org/10.3748/wjg.v20.i1.91
|
[6]
|
Barnhoorn, M.C., Hakuno, S.K., Bruckner, R.S., Rogler, G., Hawinkels, L.J., et al. (2020) Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 14, 995-1009. https://doi.org/10.1093/ecco-jcc/jjaa009
|
[7]
|
Zhao, N., Wang, G., Long, S., et al. (2021) Neutrophils-Derived Spink7 as One Safeguard against Experimental Murine Colitis. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1867, Article ID: 166125. https://doi.org/10.1016/j.bbadis.2021.166125
|
[8]
|
Guan, Q. (2019) A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019, Article ID: 7247238. https://doi.org/10.1155/2019/7247238
|
[9]
|
Kim, K.U., Kim, J., Kim, W.H., Min, H. and Choi, C.H. (2021) Treatments of Inflammatory Bowel Disease toward Personalized Medicine. Archives of Pharmacal Research, 44, 293-309. https://doi.org/10.1007/s12272-021-01318-6
|
[10]
|
Chan, H.C.H. and Ng, S.C. (2017) Emerging Biologics in Inflammatory Bowel Disease. Journal of Gastroenterology, 52, 141-150. https://doi.org/10.1007/s00535-016-1283-0
|
[11]
|
Lopetuso, L.R., Gerardi, V., Papa, V., et al. (2017) Can We Predict the Efficacy of Anti-TNF-α Agents? International Journal of Molecular Sciences, 18, Article No. 1973. https://doi.org/10.3390/ijms18091973
|
[12]
|
Molander, P., Kemppainen, H., Ilus, T. and Sipponen, T. (2020) Long-Term Deep Remission during Maintenance Therapy with Biological Agents in Inflammatory Bowel Diseases. Scand Journal of Gastroenterology, 55, 34-40. https://doi.org/10.1080/00365521.2019.1701070
|
[13]
|
Yoshida, A., Matsuoka, K., Ueno, F., Morizane, T., Endo, Y. and Hibi, T. (2021) Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflammatory Intestinal Diseases, 6, 117-122. https://doi.org/10.1159/000515361
|
[14]
|
Yi, F.M. and Wu, J.B. (2014) Biomarkers of Inflammatory Bowel Disease. Disease Markers, 2014, Article ID: 710915. https://doi.org/10.1155/2014/710915
|
[15]
|
Sakurai, T. and Saruta, M. (2023) Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion, 104, 30-41. https://doi.org/10.1159/000527846
|
[16]
|
Fine, S., Papamichael, K. and Cheifetz, A.S. (2019) Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Disease. Gastroenterology & Hepatology (NY), 15, 656-665.
|
[17]
|
Qiu, Y.D., Luo, J., Zhang, F.R., et al. (2020) Research Progress of Primary Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease. Chinese Journal of New Drugs and Clinical, 39, 513-518.
|
[18]
|
Li, L., Chen, R., Zhang, Y., et al. (2021) A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease. Frontiers in Immunology, 12, Article ID: 646673. https://doi.org/10.3389/fimmu.2021.646673
|
[19]
|
Buhl, S., Steenholdt, C., Rasmussen, M., et al. (2017) Outcomes after Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 23, 1210-1217. https://doi.org/10.1097/MIB.0000000000001117
|
[20]
|
Mould, D.R. and Green, B. (2010) Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies: Concepts and Lessons for Drug Development. BioDrugs, 24, 23-39. https://doi.org/10.2165/11530560-000000000-00000
|
[21]
|
Papamichael, K., Gils, A., Rutgeerts, P., et al. (2015) Role for Therapeutic Drug Monitoring during Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse. Inflammatory Bowel Diseases, 21, 182-197. https://doi.org/10.1097/MIB.0000000000000202
|
[22]
|
Bourchany, A., Gilletta De Saint-Joseph, C., Breton, A., Barreau, F. and Mas, E. (2020) Optimization of Biologics to Reduce Treatment Failure in Inflammatory Bowel Diseases. Current Opinion in Pharmacology, 54, 51-58. https://doi.org/10.1016/j.coph.2020.07.012
|
[23]
|
Van den Berghe, N., Verstockt, B., Tops, S., Ferrante, M., Vermeire, S. and Gils, A. (2019) Immunogenicity Is Not the Driving Force of Treatment Failure in Vedolizumab-Treated Inflammatory Bowel Disease Patients. Journal of Gastroenterology and Hepatology, 34, 1175-1181. https://doi.org/10.1111/jgh.14584
|
[24]
|
Jasurda, J.S., McCabe, R.P. and Vaughn, B.P. (2021) Adalimumab Concentration Changes after Dose Escalation in Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 43, 645-651. https://doi.org/10.1097/FTD.0000000000000849
|
[25]
|
Kennedy, N.A., Heap, G.A., Green, H.D., et al. (2019) Predictors of Anti-TNF Treatment Failure in Anti-TNF-Naive Patients with Active Luminal Crohn’s Disease: A Prospective, Multicentre, Cohort Study. The Lancet Gastroenterology & Hepatology, 4, 341-353. https://doi.org/10.1016/S2468-1253(19)30012-3
|
[26]
|
Lim, Z., Welman, C.J., Raymond, W. and Thin, L. (2020) The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn’s Disease Patients. Clinical and Translational Gastroenterology, 11, e00233. https://doi.org/10.14309/ctg.0000000000000233
|
[27]
|
Song, J.H., Hong, S.N., Lee, J.E., et al. (2019) C-Reactive Protein Reduction Rate Following Initiation of Anti-Tumor Necrosis Factor α Induction Therapy Predicts Secondary Loss of Response in Patients with Crohn’s Disease. Scand Journal of Gastroenterology, 54, 876-885. https://doi.org/10.1080/00365521.2019.1638962
|
[28]
|
Alatawi, H., Mosli, M., Saadah, O.I., et al. (2022) Attributes of Intestinal Microbiota Composition and Their Correlation with Clinical Primary Non-Response to Anti-TNF-α Agents in Inflammatory Bowel Disease Patients. Bosnian Journal of Basic Medical Sciences, 22, 412-426. https://doi.org/10.17305/bjbms.2021.6436
|
[29]
|
Brandse, J.F., Van Den Brink, G.R., Wildenberg, M.E., et al. (2015) Loss of Infliximab into Feces Is Associated with Lack of Response to Therapy in Patients with Severe Ulcerative Colitis. Gastroenterology, 149, 350-355.e2. https://doi.org/10.1053/j.gastro.2015.04.016
|
[30]
|
Ferrante, M., Vermeire, S., Katsanos, K.H., et al. (2007) Predictors of Early Response to Infliximab in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 13, 123-128. https://doi.org/10.1002/ibd.20054
|
[31]
|
Kumar, P., Vuyyuru, S.K., Das, P., et al. (2023) Serum Albumin Is the Strongest Predictor of Anti-Tumor Necrosis Factor Nonresponse in Inflammatory Bowel Disease in Resource-Constrained Regions Lacking Therapeutic Drug Monitoring. Intestinal Research, 21, 460-470. https://doi.org/10.5217/ir.2022.00128
|
[32]
|
Marin-Jimenez, I., Bastida, G., Forés, A., et al. (2020) Impact of Comorbidities on Anti-TNFα Response and Relapse in Patients with Inflammatory Bowel Disease: The VERNE Study. BMJ Open Gastroenterology, 7, e000351. https://doi.org/10.1136/bmjgast-2019-000351
|
[33]
|
Kallenberg, C.G., Mulder, A.H. and Tervaert, J.W. (1992) Antineutrophil Cytoplasmic Antibodies: A Still-Growing Class of Autoantibodies in Inflammatory Disorders. The American Journal of Medicine, 93, 675-682. https://doi.org/10.1016/0002-9343(92)90202-M
|
[34]
|
Bornstein, G., Ben-Zvi, I., Furie, N. and Grossman, C. (2019) Clinical Significance of Positive Anti-Neutrophil Cytoplasmic Antibodies without Evidence of Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis. International Journal of Rheumatic Diseases, 22, 940-945. https://doi.org/10.1111/1756-185X.13483
|
[35]
|
Reese, G.E., Constantinides, V.A., Simillis, C., et al. (2006) Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease. American Journal of Gastroenterology, 101, 2410-2422. https://doi.org/10.1111/j.1572-0241.2006.00840.x
|
[36]
|
Arias-Loste, M.T., Bonilla, G., Moraleja, I., et al. (2013) Presence of Anti-Proteinase 3 Antineutrophil Cytoplasmic Antibodies (Anti-PR3 ANCA) as Serologic Markers in Inflammatory Bowel Disease. Clinical Reviews in Allergy & Immunology, 45, 109-116. https://doi.org/10.1007/s12016-012-8349-4
|
[37]
|
Oussalah, A., Evesque, L., Laharie, D., et al. (2010) A Multicenter Experience with Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. American Journal of Gastroenterology, 105, 2617-2625. https://doi.org/10.1038/ajg.2010.345
|
[38]
|
Zhang, C.X. and Wu, X.P. (2016) Risk Factors of Crohn’s Disease with Primary Loss of Response to Infliximab. Chinese Journal of Digestion, 36, 769-771.
|
[39]
|
Lee, S.H., Walshe, M., Oh, E.H., et al. (2021) Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients with Ulcerative Colitis Starting Anti-TNF Treatment. Inflammatory Bowel Diseases, 27, 1452-1461. https://doi.org/10.1093/ibd/izaa309
|
[40]
|
Orfanoudaki, E., Gazouli, M., Foteinogiannopoulou, K., et al. (2019) Infliximab Trough Levels Are Decreasing over Time in Patients with Inflammatory Bowel Dis-ease on Maintenance Treatment with Infliximab. European Journal of Gastroenterology and Hepatology, 31, 187-191. https://doi.org/10.1097/MEG.0000000000001332
|
[41]
|
Brandse, J.F., Mathot, R.A., Van Der Kleij, D., et al. (2016) Pharmaco-kinetic Features and Presence of Antidrug Antibodies Associate with Response to Infliximab Induction Therapy in Patients with Moderate to Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 14, 251-258.e2. https://doi.org/10.1016/j.cgh.2015.10.029
|
[42]
|
Verstockt, S., Verstockt, B., Machiels, K., et al. (2021) Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 27, 1564-1575. https://doi.org/10.1093/ibd/izab032
|
[43]
|
Hermanns, H.M. (2015) Oncostatin M and Interleukin-31: Cytokines, Receptors, Signal Transduction and Physiology. Cytokine & Growth Factor Reviews, 26, 545-558. https://doi.org/10.1016/j.cytogfr.2015.07.006
|
[44]
|
West, N.R., Hegazy, A.N., Owens, B.M.J., et al. (2017) Oncostatin M Drives Intestinal Inflammation and Predicts Response to Tumor Necrosis Factor-Neutralizing Therapy in Patients with Inflammatory Bowel Disease. Nature Medicine, 23, 579-589. https://doi.org/10.1038/nm.4307
|
[45]
|
Kim, W.M., Kaser, A. and Blumberg, R.S. (2017) A Role for Oncostatin M in Inflammatory Bowel Disease. Nature Medicine, 23, 535-536. https://doi.org/10.1038/nm.4338
|
[46]
|
Carrette, F. and Surh, C.D. (2012) IL-7 Signaling and CD127 Receptor Regulation in the Control of T Cell Homeostasis. Seminars in Immunology, 24, 209-217. https://doi.org/10.1016/j.smim.2012.04.010
|
[47]
|
Jung, E.S., Choi, K., Kim, S.W., et al. (2019) ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases. Journal of Gastroenterology and Hepatology, 34, 1727-1735. https://doi.org/10.1111/jgh.14652
|
[48]
|
Pascual-Oliver, A., Casas-Deza, D., Cuarán, C., et al. (2023) HLA-DQA1*05 Was Not Associated with Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad130
|
[49]
|
González, M.R.D., Ballester, M.P., Romero-González, E., et al. (2022) Biological Treatment Interruption in Inflammatory Bowel Disease: Motivation and Predictive Factors. Gastroenterology & Hepatology, 46, 671-681.
|
[50]
|
Labarile, N., Ghosh, S., Ng, S.C., Walters, J. and Iacucci, M. (2020) Tests That Now Deserve to Be More Widely Adopted in IBD Clinical Practice. Therapeutic Advances in Gastroenterology, Vol. 13. https://doi.org/10.1177/1756284820944088
|
[51]
|
Rodríguez-Lago, I., Benítez, J.M., Sempere, L., et al. (2019) The Combination of Granulocyte-Monocyte Apheresis and Vedolizumab: A New Treatment Option for Ulcerative Colitis? Journal of Clinical Apheresis, 34, 680-685. https://doi.org/10.1002/jca.21746
|
[52]
|
Rodríguez-Lago, I., Sempere, L., Gutiérrez, A., et al. (2019) Granulocyte-Monocyte Apheresis: An Alternative Combination Therapy after Loss of Response to Anti-TNF Agents in Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 54, 459-464. https://doi.org/10.1080/00365521.2019.1600715
|
[53]
|
Wewer, M.D., Arp, L., Sarikaya, M., et al. (2022) The Use and Efficacy of Biological Therapies for Inflammatory Bowel Disease in a Danish Tertiary Centre 2010-2020. Crohn’s & Colitis 360, 4, otac041. https://doi.org/10.1093/crocol/otac041
|
[54]
|
Gil-Candel, M., Gas-cón-Cánovas, J.J., Urbieta-Sanz, E., Rentero-Redondo, L., Onteniente-Candela, M. and Iniesta-Navalón, C. (2020) Comparison of Drug Survival between Infliximab and Adalimumab in Inflammatory Bowel Disease. International Journal of Clinical Pharmacy, 42, 500-507. https://doi.org/10.1007/s11096-020-00978-6
|
[55]
|
Rodríguez-Lago, I., Abecia, L., Seoane, I., Anguita, J. and Cabriada, J.L. (2023) An in Vitro Analysis of the Interaction between Infliximab and Granulocyte-Monocyte Apheresis. Gastroenterology & Hepatology. https://doi.org/10.1016/j.gastrohep.2023.07.001
|
[56]
|
Shouval, D.S., Turner, D. and Assa, A. (2019) Position Paper: Anti-TNFα Drug and Anti-Drug Monitoring in Pediatric Patients with Inflammatory Bowel Disease. Harefuah, 158, 752-754.
|
[57]
|
Cheifetz, A.S., Abreu, M.T., Afif, W., et al. (2021) A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 116, 2014-2025. https://doi.org/10.14309/ajg.0000000000001396
|
[58]
|
Papamichael, K. and Cheifetz, A.S. (2020) Therapeutic Drug Monitoring in Patients on Biologics: Lessons from Gastroenterology. Current Opinion in Rheumatology, 32, 371-379. https://doi.org/10.1097/BOR.0000000000000713
|
[59]
|
Bqain, M., Efimov, A., Baker, D. and Kang, A.S. (2021) Immunogenicity of Biologics Used in the Treatment of Inflammatory Bowel Disease. Human Antibodies, 29, 225-235. https://doi.org/10.3233/HAB-210449
|
[60]
|
Sablich, R., Urbano, M.T., Scarpa, M., Scognamiglio, F., Paviotti, A. and Savarino, E. (2023) Vedolizumab Is Superior to Infliximab in Biologic Naive Patients with Ulcerative Colitis. Scientific Reports, 13, Article No. 1816. https://doi.org/10.1038/s41598-023-28907-3
|